GSK's Competitive Edge, Surpasses Pfizer in Respiratory Syncytial Virus Vaccine Sales

GSK GSK has reportedly taken an early lead in the race for respiratory syncytial virus (RSV) vaccine dominance, surpassing Pfizer Inc PFE, which previously dominated the COVID-19 vaccine market. 

GSK's RSV vaccine has gained significant traction in the U.S., with IQVIA data revealing that it accounts for nearly two-thirds of RSV shots administered since early September.

Related: Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants.

This early success can be attributed to GSK's strategic partnership with CVS Health Corp CVS, the largest pharmacy chain in the U.S. and a key player in the retail vaccine market. 

The exclusive availability of GSK's RSV vaccine at CVS Health has given the British drugmaker a competitive edge, Reuters noted, citing analysts and industry experts.

Price considerations also appear to play a role, as GSK's vaccine is listed at a slight discount compared to Pfizer's offering. The price point may be swaying independent pharmacists' decisions in favor of GSK's product.

As both companies seek to expand their vaccine sales, these shots represent a potential source of revenue to counteract the upcoming generic competition facing older medicines like Pfizer's Ibrance and GSK's Dovato.

While GSK's early lead is significant, it remains to be seen how future decisions by major pharmacy chains like Walgreens Boots Alliance Inc WBA, Walmart Inc WMT, and Rite Aid Corp.RADCQ may influence the RSV vaccine landscape.

Price Action: GSK shares are up 2.24% at $35.34 on the last check Monday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.